A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland

Publikation

A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland

Wissenschaftlicher Artikel/Review - 16.01.2020

Panje Cédric, Schwenkglenks M, Gautschi O, Plasswilm Ludwig, Aebersold D M, Dedes K J, Lorez M, Pardo E, Barbier M, Lupatsch J E, Swiss Group for Clinical Cancer Research (SAKK)

Panje, Cédric

Lupatsch, J E

Barbier, M

Pardo, E

Lorez, M

Dedes, K J

Aebersold, D M

Plasswilm, Ludwig

Chefarzt/Chefärztin
Radio-Onkologie · Dept. IV

A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland

Panje, Cédric

Lupatsch, J E

Barbier, M

Pardo, E

Lorez, M

Dedes, K J

Aebersold, D M

Plasswilm, Ludwig

Gautschi, O

Schwenkglenks, M

Swiss Group for Clinical Cancer Research (SAKK),